poisar

Stocks · News reference

New AI ETF Bets on Healthcare's $9 Trillion Opportunity

Chandrima Sanyal

Tema's new Healthcare AI ETF (HLTH), targets AI-powered drug discovery, diagnostics, robotics and patient care.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

CYTKHLTHILMNTXG
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Na

    Will Camzyos' Long-Term Benefits Strengthen BMY's Growth Outlook?

    Bristol Myers Squibb's Camzyos demonstrated durable reductions in LVOT obstruction over five years with 97.4% of patients achieving target gradients. Sales surged 74% year-over-year to $729 million in H1 2026. The company seeks FDA approval for adolescents with a decision expected by September 30, 2026. However, competition is intensifying with Cytokinetics' Myqorzo approved in December 2025 and Edgewise Therapeutics advancing EDG-7500 in clinical trials.

    BMYCELGRCYTKEWTX
  2. Na

    Cytokinetics to Participate in September Investor Conferences

    Cytokinetics announced that management will participate in multiple investor conferences in September 2026. The company highlighted positive results from its ACACIA-HCM Phase 3 clinical trial for aficamten in non-obstructive hypertrophic cardiomyopathy (nHCM), with plans to submit a Supplemental New Drug Application in Q4 2026. The trial demonstrated statistically significant improvements in both patient-reported and physician-assessed endpoints.

    CYTK
  3. Na

    Can CYTK's Aficamten Strengthen Its HCM Growth Prospects?

    Cytokinetics announced additional positive results from ACACIA-HCM and MAPLE-HCM studies showing aficamten improved cardiac structure and diastolic function in non-obstructive HCM patients, and outperformed metoprolol in obstructive HCM. The company plans to file for nHCM approval in Q4 2026, potentially expanding the drug's addressable market. Myqorzo received FDA approval in December 2025 for obstructive HCM treatment.

    CYTKBMYCELGREWTX
  6. Market Updates

    The Market Just Told You Which Layer Of AI Biology It Is Paying For

    Recent earnings in life sciences technology reveal that the market is rewarding companies with proprietary data and systems of record over those selling software or AI models alone. Veeva Systems beat expectations with strong AI product adoption, while Certara missed on modest software growth and Recursion Pharmaceuticals fell short on revenue expectations. MindWalk Holdings, which owns curated biological data infrastructure, is positioned to benefit from this trend with its HYFT Technology and newly launched ReefIQ platform, though it remains unprofitable with modest recurring revenue.

    VEEVCERTRXRXILMNHYFT